Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931303 | 0.89 | DRD2 (0.47) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL1931683 | 0.89 | DRD2 (0.47) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL14964347 | 0.89 | DRD2 (0.47) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL1931738 | 0.89 | DRD2 (0.47) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL2364895 | 0.86 | DRD2 (0.44) | DRD2SCN3ASCN4ASTAT6TAS1R3 | |
| SCHEMBL2364894 | 0.86 | DRD2 (0.44) | DRD2SCN3ASCN4ASTAT6TAS1R3 | |
| SCHEMBL19856894 | 0.86 | DRD2 (0.45) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL19856892 | 0.86 | DRD2 (0.45) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL8000170 | 0.85 | DRD2 (0.46) | DRD2STAT6TAS1R3TAS1R1CYP51A1 | |
| SCHEMBL7943270 | 0.84 | STAT6 (0.48) | DRD2SCN3ASCN4ASTAT6TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | PARP1 3909/4885DRD2 928/4885SCN3A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.